"Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial." by Michael Lock

Article

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.

BMC Cancer (2012)

Michael Lock, University of Western Ontario

Link Find in your library

Disciplines

Health and Medical Administration,
Medical Biophysics,
Medical Cell Biology,
Medical Education,
Oncology and
Translational Medical Research

Publication Date

Summer July 23, 2012

Citation Information

Michael Lock. "Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial." BMC Cancer (2012)
Available at: http://works.bepress.com/michael_lock/6/